HIV-1 protease inhibitors. A review for clinicians - PubMed (original) (raw)
Review
. 1997 Jan 8;277(2):145-53.
Affiliations
- PMID: 8990341
Review
HIV-1 protease inhibitors. A review for clinicians
S G Deeks et al. JAMA. 1997.
Abstract
Objective: The clinical care of people infected with human immunodeficiency virus (HIV) has been substantially affected by the introduction of HIV-specific protease inhibitors (PIs). The 4 PIs available are saquinavir mesylate, ritonavir, indinavir sulfate, and nelfinavir mesylate. Comparison studies have not been reported; therefore, an assessment of the available data to aid clinicians and patients in choosing appropriate treatment will be presented.
Data sources: A systematic review of peer-reviewed publications, abstracts from national and international conferences, and product registration information through September 1996.
Study selection and data extraction: Criteria used to select studies include their relevance to PIs, having been published in the English language, and pertinence for clinicians. Data quality and validity included the venue of the publication and relevance to clinical care.
Data synthesis: Oral adminstration of ritonavir, indinavir, or nelfinavir generates sustainable drug serum levels to effectively inhibit the protease enzyme; however, saquinavir may not generate sustained levels necessary to inhibit the protease enzyme. Patients treated with ritonavir, indinavir, or nelfinavir experience similar reductions in viral load and increases in CD4+ lymphocytes; smaller effects occur among those treated with saquinavir. Two randomized placebo-controlled studies conducted among patients with severe immune system suppression and substantial zidovudine treatment experience demonstrated reduced HIV disease progression and reduced mortality with PI treatment. Genotypic resistance to PIs occurs; the clinical relevance of resistance is unclear. The costs of these agents including required monitoring impose new and substantial costs.
Conclusions: The PIs have emerged as critical drugs for people with HIV infection. Optimal use involves combination with reverse transcriptase inhibitors. Resistance develops to each agent, and cross-resistance is likely. These agents must be used at full doses with attention to ensuring patient compliance. The expense of these agents may be offset by forestalling disease progression and death and returning people to productive life. Selecting the initial PI must be individualized, and factors to consider include proven activity, possible toxicities, dosing regimens, drug interactions, and costs.
Similar articles
- The safety and antiviral effect of protease inhibitors in children.
Temple ME, Koranyi KI, Nahata MC. Temple ME, et al. Pharmacotherapy. 2001 Mar;21(3):287-94. doi: 10.1592/phco.21.3.287.34202. Pharmacotherapy. 2001. PMID: 11253853 - Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
Ruiz L, Nijhuis M, Boucher C, Puig T, Bonjoch A, Martínez-Picado J, Marfil S, de Jong D, Burger D, Arnó A, Balagué M, Clotet B. Ruiz L, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):19-28. doi: 10.1097/00042560-199809010-00003. J Acquir Immune Defic Syndr Hum Retrovirol. 1998. PMID: 9732064 Clinical Trial. - The choice of HIV protease inhibitor: indinavir is currently the best option.
[No authors listed] [No authors listed] Prescrire Int. 1999 Apr;8(40):55-60. Prescrire Int. 1999. PMID: 10848067 Review. - Combinations of protease inhibitors.
[No authors listed] [No authors listed] TreatmentUpdate. 1998 Apr;10(2):1-3. TreatmentUpdate. 1998. PMID: 11365433 - HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR, Cinti SK, Carver PL, Kazanjian PH. Kaul DR, et al. Pharmacotherapy. 1999 Mar;19(3):281-98. doi: 10.1592/phco.19.4.281.30937. Pharmacotherapy. 1999. PMID: 10221367 Review.
Cited by
- Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.
Quercia R, Di Perri G, Pein C, Bodie J, Singh RSP, Hendrick V, Boffito M. Quercia R, et al. Infect Dis Ther. 2024 May;13(5):1005-1017. doi: 10.1007/s40121-024-00959-6. Epub 2024 Apr 12. Infect Dis Ther. 2024. PMID: 38609668 Free PMC article. Review. - Proteolysis in Reproduction: Lessons From Gene-Modified Organism Studies.
Kiyozumi D, Ikawa M. Kiyozumi D, et al. Front Endocrinol (Lausanne). 2022 May 4;13:876370. doi: 10.3389/fendo.2022.876370. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600599 Free PMC article. Review. - Optimized pharmacological control over the AAV-Gene-Switch vector for regulable gene therapy.
Cheng S, van Gaalen MM, Bähr M, Garea-Rodriguez E, Kügler S. Cheng S, et al. Mol Ther Methods Clin Dev. 2021 Aug 8;23:1-10. doi: 10.1016/j.omtm.2021.07.007. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34552998 Free PMC article. - HIV infection is linked with reduced error-related default mode network suppression and poorer medication management abilities.
Flannery JS, Riedel MC, Salo T, Poudel R, Laird AR, Gonzalez R, Sutherland MT. Flannery JS, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Dec 20;111:110398. doi: 10.1016/j.pnpbp.2021.110398. Epub 2021 Jul 3. Prog Neuropsychopharmacol Biol Psychiatry. 2021. PMID: 34224796 Free PMC article. - Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs.
Marcatili M, Stefana A, Colmegna F, di Giacomo E, D'Amico E, Capuzzi E, Dakanalis A, Clerici M. Marcatili M, et al. Psychiatry Clin Neurosci. 2021 Apr;75(4):145-146. doi: 10.1111/pcn.13205. Epub 2021 Feb 25. Psychiatry Clin Neurosci. 2021. PMID: 33511703 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous